US29530P1021 - Common Stock

We assign a fundamental rating of **7** out of 10 to **ERIE**. **ERIE** was compared to 141 industry peers in the **Insurance** industry. **ERIE** gets an excellent profitability rating and is at the same time showing great financial health properties. **ERIE** shows excellent growth, but is valued quite expensive already. With these ratings, **ERIE** could be worth investigating further for growth and quality investing!.

In the past year **ERIE** had a positive cash flow from operations.

In the past 5 years **ERIE** has always been profitable.

Each year in the past 5 years **ERIE** had a positive operating cash flow.

Looking at the **Return On Equity**, with a value of **29.00%**, **ERIE** belongs to the top of the industry, outperforming **94.24%** of the companies in the same industry.

Measured over the past 3 years, the **Average Return On Invested Capital** for **ERIE** is significantly above the industry average of **4.02%**.

The last **Return On Invested Capital** (**24.99%**) for **ERIE** is above the 3 year average (**19.35%**), which is a sign of increasing profitability.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 19.7% | ||

ROE | 29% | ||

ROIC | 24.99% |

ROA(3y)14.89%

ROA(5y)14.85%

ROE(3y)23.22%

ROE(5y)24.46%

ROIC(3y)19.35%

ROIC(5y)19.18%

In the last couple of years the **Profit Margin** of **ERIE** has grown nicely.

Looking at the **Operating Margin**, with a value of **17.04%**, **ERIE** is in the better half of the industry, outperforming **71.94%** of the companies in the same industry.

In the last couple of years the **Gross Margin** of **ERIE** has grown nicely.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 17.04% | ||

PM (TTM) | 14.95% | ||

GM | 17.04% |

OM growth 3Y6.08%

OM growth 5Y1.94%

PM growth 3Y5.67%

PM growth 5Y2.44%

GM growth 3Y6.08%

GM growth 5Y1.95%

The number of shares outstanding for **ERIE** has been increased compared to 1 year ago.

There is no outstanding debt for **ERIE**. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0 | ||

Debt/FCF | 0 | ||

Altman-Z | 22.69 |

ROIC/WACC2.9

WACC8.62%

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.32 | ||

Quick Ratio | 1.32 |

The **Earnings Per Share** has been growing by **9.13%** on average over the past years. This is quite good.

The **Revenue** has grown by **16.92%** in the past year. This is quite good.

EPS 1Y (TTM)50%

EPS 3Y14.99%

EPS 5Y9.13%

EPS Q2Q%39.11%

Revenue 1Y (TTM)16.92%

Revenue growth 3Y8.82%

Revenue growth 5Y6.53%

Sales Q2Q%17.93%

The **Revenue** is expected to grow by **14.32%** on average over the next years. This is quite good.

EPS Next Y35.48%

EPS Next 2Y26.58%

EPS Next 3Y15.84%

EPS Next 5YN/A

Revenue Next Year17.31%

Revenue Next 2Y14.32%

Revenue Next 3YN/A

Revenue Next 5YN/A

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

A **Price/Earnings** ratio of **52.07** indicates a quite expensive valuation of **ERIE**.

Based on the **Price/Earnings** ratio, **ERIE** is valued a bit more expensive than the industry average as 78.42% of the companies are valued more cheaply.

Compared to an average S&P500 **Price/Earnings** ratio of **30.72**, **ERIE** is valued quite expensively.

Based on the **Price/Forward Earnings** ratio of **38.63**, the valuation of **ERIE** can be described as expensive.

Based on the **Price/Forward Earnings** ratio, **ERIE** is valued a bit more expensive than 79.14% of the companies in the same industry.

The average S&P500 **Price/Forward Earnings** ratio is at **22.18**. **ERIE** is valued rather expensively when compared to this.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 52.07 | ||

Fwd PE | 38.63 |

Compared to the rest of the industry, the **Price/Free Cash Flow** ratio of **ERIE** indicates a slightly more expensive valuation: **ERIE** is more expensive than 77.70% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 85.82 | ||

EV/EBITDA | N/A |

The **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

The excellent profitability rating of **ERIE** may justify a higher PE ratio.

A more expensive valuation may be justified as **ERIE**'s earnings are expected to grow with **15.84%** in the coming years.

PEG (NY)1.47

PEG (5Y)5.7

EPS Next 2Y26.58%

EPS Next 3Y15.84%

With a yearly dividend of 0.95%, **ERIE** is not a good candidate for dividend investing.

With a **Dividend Yield** of **0.95**, **ERIE** pays less dividend than the S&P500 average, which is at **2.22**.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 0.95% |

On average, the dividend of **ERIE** grows each year by **7.15%**, which is quite nice.

Dividend Growth(5Y)7.15%

Div Incr Years3

Div Non Decr Years3

The dividend of **ERIE** is growing, but earnings are growing more, so the dividend growth is sustainable.

DP43.29%

EPS Next 2Y26.58%

EPS Next 3Y15.84%

**ERIE INDEMNITY COMPANY-CL A**

NASDAQ:ERIE (10/8/2024, 9:47:56 AM)

**527.965**

**+5.99 (+1.15%) **

Chartmill FA Rating

GICS SectorFinancials

GICS IndustryGroupInsurance

GICS IndustryInsurance

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap27.61B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 0.95% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 52.07 | ||

Fwd PE | 38.63 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)1.47

PEG (5Y)5.7

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 19.7% | ||

ROE | 29% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 17.04% | ||

PM (TTM) | 14.95% | ||

GM | 17.04% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.32

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.32 | ||

Quick Ratio | 1.32 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)50%

EPS 3Y14.99%

EPS 5Y

EPS Q2Q%

EPS Next Y35.48%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)16.92%

Revenue growth 3Y8.82%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y